# Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/results-from-the-phase-iii-randomized-trial-of-onartuzumab-plus-erlotinib-versus/

## Facts

| Field | Value |
| --- | --- |
| Author Names | David R. Spigel,Martin J. Edelman,Kenneth J. O’Byrne,Luis Paz‐Ares,Simonetta Mocci,See Phan,David S. Shames,Dustin Smith,Wei Yu,Virginia Paton,Tony Mok |
| Citations | 328 |
| DOI | 10.1200/jco.2016.69.2160 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2562169753 |
| PMID | 27937096 |
| Type | article |
| Year | 2017 |

## Paper authors

- [David R. Spigel](https://scholariq.org/researchers/david-r-spigel/)
- [Martin J. Edelman](https://scholariq.org/researchers/martin-j-edelman/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.